地诺单抗对骨转移能有多大效果？

Tumor bone metastasis is a common occurrence in all types of tumors. When cancer cells metastasize to bones, the common symptoms are bone damage and severe pain. Bone metastasis often occurs in the lumbar spine, thoracic spine, femur and other parts. Once bone metastasis in these parts occurs, if it cannot be treated in time or is handled improperly, it will lead to complications, loss of mobility or death.

The so-called bone transfer acupuncture is a drug that can clinically treat or prevent bone metastasis. The drug that is used more clinically in China is called "zoledronic acid", but one of the biggest side effects of this acupuncture is that it may cause femoral head necrosis. The reputation among the patient group is not very good, so the editor today introduces a more suitable bone transfer drug-denosumab (denosumab). The trade name of this "denosumab" is XGEVA or PROLIA. It was originally used to treat osteoporosis in menopausal women. The R&D manufacturer is AMGEN, and it was approved by the FDA in 2010.

Denosumab is a RANK ligand (RANKL) inhibitor with a different mechanism of action than currently approved drugs that reduce skeletal complications of tumors. It is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It prevents RANKL from binding to its receptor substances, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density.

The key points for the use of this drug are as follows: injection dose - 120mg/time; injection cycle - 4 weeks/time; injection method - subcutaneous injection; injection duration - at least 6 months; auxiliary matters - calcium and vitamin D supplementation if necessary to prevent hypocalcemia; denosumab global clinical data, clinical results show that compared to zoledronic acid, denosumab (desotumab) effectively delays the incidence of first bone metastasis related: lung cancer and other solid tumors - Denosumab (Denosumab) vs. zoledronic acid 20.5 months vs. 16.3 months; Prostate cancer - denosumab vs. zoledronic acid 20.7 months vs. 17.1 months.

The above is the therapeutic effect of denosumab (desosomeumab). I hope it can help everyone.